Boston Scientific Corporation (BSX)
| Market Cap | 56.02B |
| Revenue (ttm) | 12.33B |
| Net Income (ttm) | 828.00M |
| Shares Out | 1.43B |
| EPS (ttm) | 0.57 |
| PE Ratio | 68.65 |
| Forward PE | 19.53 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,236,571 |
| Open | 38.46 |
| Previous Close | 38.14 |
| Day's Range | 38.22 - 39.42 |
| 52-Week Range | 34.98 - 47.50 |
| Beta | 0.85 |
| Analysts | Buy |
| Price Target | 49.46 (+26.4%) |
| Earnings Date | Oct 25, 2022 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and r... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 32 analysts, the average rating for BSX stock is "Buy." The 12-month stock price forecast is 49.46, which is an increase of 26.40% from the latest price.
News
Boston Scientific (BSX) Benefits From New Buyouts, FX Woes Stay
Boston Scientific's (BSX) organic growth performance is strong across all regions where most of its businesses are growing at the same pace or faster than their competitors in the respective markets.
Here's Why You Should Retain Boston Scientific (BSX) For Now
Investors are optimistic about Boston Scientific's (BSX) impressive top-line results and notable acquisitions.
Late-Breaking Data from PROTECTED TAVR Trial Demonstrate Reduced Risk of Disabling Stroke, Low Complication Rate with...
Results from largest randomized TAVR trial to date presented at TCT 2022 MARLBOROUGH, Mass. , Sept. 17, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) has announced results from the PROTE...
Boston Scientific's (BSX) WATCHMAN FLX to Offer DAPT in the US
Boston Scientific (BSX) to offer updated labeling for WATCHMAN FLX device after receiving FDA approval.
Boston Scientific Receives FDA Approval for Expanded Labeling of WATCHMAN FLX™ LAAC Device for Dual Anti-Platelet The...
WATCHMAN FLX now the only LAAC technology in the United States that allows for either DAPT or OAC immediately following implantation MARLBOROUGH, Mass. , Sept. 6, 2022 /PRNewswire/ -- Boston Scientific ...
Boston Scientific (BSX) Grows Operationally Amid Macro Issues
In the Asia Pacific region, Boston Scientific (BSX) grows operationally with notable performance in Japan, India and the ASEAN countries.
Boston Scientific (BSX) Signs Obsidio-Acquisition Agreement
Boston Scientific's (BSX) latest acquisition will add the FDA-approved GEM technology to its interventional oncology and embolization portfolio.
Boston Scientific Announces Upcoming Conference Schedule
MARLBOROUGH, Mass. , Aug. 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor events.
Boston Scientific Announces Acquisition of Obsidio, Inc.
Company to add novel technology cleared for use in peripheral vasculature to interventional oncology and embolization portfolio MARLBOROUGH, Mass. , Aug. 15, 2022 /PRNewswire/ -- Boston Scientific Corpo...
Nevro and Boston Scientific Announce the Settlement of Their Ongoing Intellectual Property Litigations
Parties Reach an Agreement that Concludes Outstanding Intellectual Property Disputes REDWOOD CITY, Calif. , Aug. 1, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO) and Boston Scientific Corp. (NYSE: BSX) ...
Boston Scientific (BSX) Q2 Earnings Beat, Margins Decline
Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.
Boston Scientific (BSX) Tops Q2 Earnings and Revenue Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of 4.76% and 0.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific Narrowly Tops Second-Quarter Expectations; Shares Surge
Boston Scientific narrowly topped second-quarter estimates Tuesday, but BSX stock surged higher in premarket action. The post Boston Scientific Narrowly Tops Second-Quarter Expectations; Shares Surge ap...
Boston Scientific tops profit and sales expectations, but trims full-year outlook
Boston Scientific Corp. BSX, -0.11% reported Wednesday second-quarter profit and sales that topped expectations, but trimmed its full-year outlook, saying it maintained "strong" market positions amid co...
Boston Scientific Announces Results for Second Quarter 2022
MARLBOROUGH, Mass. , July 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.244 billion during the second quarter of 2022, growing 5.4 percent on a reported ba...
MedTech Stocks' Earnings Due on Jul 27: BSX, HOLX & ALGN
MedTech companies' results are likely to reflect a rebound in the base business. Let's see how BSX, HOLX and ALGN fare this time.
What To Expect From Boston Scientific Stock Following Q2 Earnings?
Boston Scientific (NYSE: BSX) is scheduled to report its Q2 2021 results on Wednesday, July 27. We expect the company to report revenues and earnings in line with the consensus estimates.
PETQ vs. BSX: Which Stock Is the Better Value Option?
PETQ vs. BSX: Which Stock Is the Better Value Option?
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Boston Scientific (BSX) in Q2 Earnings?
Within the PI business of Boston Scientific (BSX), Q2 sales are expected to have been strong, banking on the strong performance of the drug-eluting franchise.
Should You Buy Boston Scientific Stock At $38?
Boston Scientific's revenue grew 13% to $12.2 billion over the last twelve months, compared to $10.7 billion in 2019, primarily led by higher sales for its peripheral interventions, endoscopy, and women...
What's Happening With Boston Scientific Stock?
Boston Scientific stock (NYSE: BSX) has seen a 9% fall in a month, in line with the broader S&P500, which is down 8%.
Boston Scientific Announces Conference Call Discussing Second Quarter 2022 Results
MARLBOROUGH, Mass. , June 29, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the second quarter ...
Seven reasons the beleaguered biotech sector is now a ‘buy'
If you have the discipline to think long-term as an investor, this is the time to take advantage of the steep discounts on great biotechnology companies.
Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout
According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.